Forte Biosciences Inc (FBRX)Healthcare | Biotechnology | Dallas, United States |
USD
|
Hot Take ↕ | Oct. 10, 2026, 2:10 p.m. UTC
The immediate catalyst is undeniable: a massive 78% rally driven by positive Phase 1b vitiligo data for FB102, which has pushed the stock to its 52-week high and triggered an 'overweight' initiation from Barclays. This creates a high-conviction short-term momentum play where the market is aggressively re-rating the asset based on clinical proof. However, the long-term outlook remains neutral due to a complete lack of price history; without multi-year data to verify sustained revenue growth or a fortress balance sheet, the business quality cannot be confirmed despite the promising trial results. Furthermore, the company is burning significant cash with negative operating and free cash flows, and the negative earnings per dollar confirms it is a pure growth story with no current profitability. There is no dividend to provide income, making this a speculative vehicle entirely dependent on future clinical milestones rather than current fundamentals. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 1,634,427,392 |
| Forward P/E | -18.89 |
| Beta | 2.65 |
| Website | https://www.fortebiorx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 6.2907195 |
| Address1 | 3,060 Pegasus Park Drive |
| Address2 | Building 6 |
| All Time High | 1,349.75 |
| All Time Low | 4.11 |
| Ask | 98.52 |
| Ask Size | 200 |
| Average Daily Volume10 Day | 1,690,927 |
| Average Volume | 1,511,439 |
| Average Volume10Days | 1,690,927 |
| Beta | 2.645 |
| Bid | 76.99 |
| Bid Size | 4,200 |
| Book Value | 7.52 |
| City | Dallas |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Currency | USD |
| Current Price | 76.99 |
| Current Ratio | 10.01 |
| Date Short Interest | 1,786,665,600 |
| Day High | 77.0 |
| Day Low | 76.96 |
| Ebitda | -94,721,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -18.376 |
| Enterprise Value | 1,740,604,672 |
| Exchange | NCM |
| Exchange Timezone Name | UTC |
| Fifty Day Average | 55.1828 |
| Fifty Two Week High | 77.2 |
| Fifty Two Week Low | 10.11 |
| Financial Currency | USD |
| First Trade Date Epoch Utc | 1,784,295,000 |
| Float Shares | 18,667,811 |
| Forward Eps | -4.075 |
| Forward P E | -18.893251 |
| Free Cashflow | -41,293,500 |
| Full Time Employees | 23 |
| Fullday Change | 0.0 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 76.99 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Held Percent Insiders | 0.02062 |
| Held Percent Institutions | 0.96650004 |
| Implied Shares Outstanding | 21,229,087 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,724,803,200 |
| Last Split Factor | 1:25 |
| Long Business Summary | Forte Biosciences, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for autoimmune and autoimmune-related diseases. The company offers products, such as its lead product candidate FB102, a proprietary molecule with applications for celiac disease, vitiligo, and alopecia areata; and services, including the clinical development and management of its Phase 2 clinical trials. Forte Biosciences, Inc. was incorporated in 2007 and is based in Dallas, Texas. As of August 27, 2026, Forte Biosciences, Inc. operates as a subsidiary of argenx SE. |
| Long Name | Forte Biosciences Inc |
| Market Cap | 1,634,427,392 |
| Max Age | 86,400 |
| Message Board Id | finmb_594626683 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -87,937,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,634,427,408 |
| Number Of Analyst Opinions | 4 |
| Open | 76.97 |
| Operating Cashflow | -71,976,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 310 618 6994 |
| Previous Close | 76.99 |
| Price Hint | 2 |
| Price To Book | 10.238031 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.822 |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.5 |
| Regular Market Day High | 77.0 |
| Regular Market Day Low | 76.96 |
| Regular Market Open | 76.97 |
| Regular Market Previous Close | 76.99 |
| Regular Market Volume | 1,399,801 |
| Return On Assets | -0.37794 |
| Return On Equity | -0.62277 |
| Sand P52 Week Change | 0.1570785 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 21,229,087 |
| Shares Percent Shares Out | 0.0769 |
| Shares Short | 1,632,328 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 2,060,636 |
| Short Name | Forte Biosciences, Inc. |
| Short Percent Of Float | 0.0774 |
| Short Ratio | 0.82 |
| State | TX |
| Symbol | FBRX |
| Target High Price | 77.0 |
| Target Low Price | 61.0 |
| Target Mean Price | 73.0 |
| Target Median Price | 77.0 |
| Time Zone Full Name | America/New_York |
| Time Zone Short Name | EDT |
| Total Cash | 198,460,000 |
| Total Cash Per Share | 7.88 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.57 |
| Trailing Peg Ratio | None |
| Two Hundred Day Average | 33.25001 |
| Underlying Symbol | FBRX |
| Uuid | f04f9b0f-d548-36f2-85cf-42c97dc26955 |
| Volume | 1,399,801 |
| Website | https://www.fortebiorx.com |
| Zip | 75,247 |